A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome

OBJECTIVE: To compare the ICSI outcome of two multidose gonadotropin releasing hormone antagonist (GnRH-ant) in women with polycystic ovary syndrome (PCOS). DESIGN: A prospective, randomized, single-blind study in a referral center for assisted reproduction. MATERIALS AND METHODS: Eighty two women with the diagnosis of PCOS were randomly assigned to either multidose ganirelix or multidose cetrorelix, started when the dominant follicle has reached >13 mm in diameter. The sample size calculation was based on an average of 36% clinical pregnancy rate. To find a 16% change in the clinical pregnancy rate with a power of 0.80 at a ¼ 0.05, the total sample size required was 71 women. In order to achieve adequate sample size after cycle cancellation 82 women were recruited in the study. Chi-square and student-t test were used as appropriate. RESULTS: The mean age, the body mass index, infertility period, cleavage rate, fertilisation rates were similar in the two groups (P>0.05). The cycle cancellation rate was 14.6% in the ganirelix group and 12.2% in the cetrorelix group (P¼0.07). The number of good quality embryos obtained was 2.8 0.6 in the ganirelix group while it was 2.6 0.5 in the cetrorelix group. The clinical pregnancy rate was 40% in the ganirelix group and 30.6% in the cetrorelix group (P¼0.4). Take home baby rate were 31.4% in the ganirelix group and 22.2% in the cetrorelix group (P¼0.38). CONCLUSIONS: The two GnRH-ant were found to have similar ICSI outcomes in PCOS patients.